ヒト免疫不全ウイルス治療薬の世界市場レポート 2025年

ヒト免疫不全ウイルス治療薬市場規模は、今後数年間で力強い成長が見込まれます。2029年には185億7,000万米ドルに成長し、CAGRは5.6%となります。予測期間中の成長は、HIV患者数の増加、HIVスクリーニングへの取り組みの増加、自発的検査率の伸び、無防備な性行為の急増、政府主導のプログラムの拡大などに起因すると考えられます。予測期間における主な動向としては、技術の進歩、AIを活用した医薬品開発、長時間作用型注射治療の出現、遠隔医療の統合、CRISPRを活用した遺伝子治療の探求などが挙げられます。

無防備な性行為の発生率の上昇は、ヒト免疫不全ウイルス（HIV）治療薬市場の成長を促進する主要因です。無防備な性行為（バリア保護具を使用しない性行為と定義）は、HIVを含む性感染症（STI）のリスクを著しく高める。この動向は、特に青少年や若年成人の間で、避妊法へのアクセスが限られていることや、包括的な性教育が行われていないことによって悪化しています。HIV治療薬は、ウイルス量を抑制することで感染を防ぎ、患者の転帰を改善するという重要な役割を担っています。例えば、米国疾病予防管理センター（CDC）が2024年11月に発表した報告書によると、2023年に調査した米国の高校生の32％が性交渉の経験があると回答し、48％が直近の性交渉でコンドームを使用しませんでした。これらの統計は、効果的なHIV介入に対する緊急の必要性を強調し、抗レトロウイルス療法に対する需要の高まりを裏付けています。

HIV治療薬市場の主要企業は、有効性を向上させ、薬剤耐性を最小限に抑え、患者のアドヒアランスを促進するために、併用療法戦略を進めています。併用療法は、2種類以上の薬剤を同時に使用してHIVを治療するもので、ウイルス学的コントロールの改善、錠剤負担の軽減、耐性発現リスクの低下など、いくつかの利点があります。2022年12月、米国のバイオ医薬品会社ギリアド・サイエンシズ社は、新規の長時間作用型キャプシド阻害薬であるサンレンカ（レナカパビル）のFDA承認を取得しました。他の抗レトロウイルス薬との併用で承認されたサンレンカは、多剤耐性HIV-1の成人を対象としています。同クラスのHIV治療薬としては初めてであり、年2回の投与レジメンを提供することで、利便性と服薬アドヒアランスを大幅に向上させます。今回の承認は、強力かつ持続的なウイルス学的抑制を示したCAPELLA試験によって裏付けられました。情勢のような革新は、特に複雑な治療歴を持つ患者にとって、治療の展望を再構築するものです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のヒト免疫不全ウイルス治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のヒト免疫不全ウイルス治療薬市場：成長率分析
• 世界のヒト免疫不全ウイルス治療薬市場の実績：規模と成長、2019年～2024年
• 世界のヒト免疫不全ウイルス治療薬市場の予測：規模と成長、2024年～2029年、2034年
• 世界のヒト免疫不全ウイルス治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のヒト免疫不全ウイルス治療薬市場：薬剤タイプ別、実績と予測、2019年～2024年、2024年～2029年、2034年
• ブランド医薬品
• ジェネリック医薬品
• 世界のヒト免疫不全ウイルス治療薬市場：薬剤クラス別、実績と予測、2019年～2024年、2024年～2029年、2034年
• ヌクレオシド類似体逆転写酵素阻害剤（NRTIS）
• 非ヌクレオシド系逆転写酵素阻害剤（NNRTIS）
• 侵入および融合阻害剤
• プロテアーゼ阻害剤（Pis）
• インテグラーゼ阻害剤
• 共受容体拮抗薬
• 世界のヒト免疫不全ウイルス治療薬市場：流通チャネル別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 病院薬局
• オンライン薬局
• 小売薬局
• 世界のヒト免疫不全ウイルス治療薬市場：エンドユーザー別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 病院と診療所
• 専門センター
• 世界のヒト免疫不全ウイルス治療薬市場、ブランド医薬品の種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• ビクタルヴィ
• トリウメク
• ゲンヴォヤ
• ジュルカ
• ドヴァート
• アイセントレス
• プレジスタ
• 世界のヒト免疫不全ウイルス治療薬市場、ジェネリック医薬品の種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• テノホビルジソプロキシルフマル酸塩（TDF）
• ラミブジン
• エファビレンツ
• ジドブジン
• ネビラピン
• アバカビル
• リトナビル

第7章 地域別・国別分析

• 世界のヒト免疫不全ウイルス治療薬市場：地域別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 世界のヒト免疫不全ウイルス治療薬市場：国別、実績と予測、2019年～2024年、2024年～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ヒト免疫不全ウイルス治療薬市場：競合情勢
• ヒト免疫不全ウイルス治療薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • F Hoffmann La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Sanofi SA
• Bristol Myers Squibb Company（BMS）
• Novartis International AG
• GlaxoSmithKline plc（GSK）
• Gilead Sciences Inc.
• Moderna Inc.
• BioNTech SE
• Teva Pharmaceutical Industries Ltd.
• Boehringer Ingelheim International GmbH
• Aurobindo Pharma Limited
• Cipla Limited
• Hetero Labs Limited
• Gilead Sciences Inc./Kite Pharma Inc.（for CAR T HIV cure research）
• Vir Biotechnology Inc.
• Theratechnologies Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ヒト免疫不全ウイルス治療薬市場2029年：新たな機会を提供する国
• ヒト免疫不全ウイルス治療薬市場2029年：新たな機会を提供するセグメント
• ヒト免疫不全ウイルス治療薬市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Human immunodeficiency virus (HIV) therapeutics refer to treatments and medications aimed at managing and suppressing HIV infection, primarily through antiretroviral therapy (ART). These therapies work to lower the viral load, prevent the progression to AIDS, and enhance the quality of life for people living with HIV.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary drug types in HIV therapeutics include branded and generic drugs. Branded drugs are patented treatments developed and marketed under specific trade names after extensive research and clinical evaluation to ensure efficacy and safety. The major drug classes encompass nucleoside-analog reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), entry and fusion inhibitors, protease inhibitors (PIs), integrase inhibitors, and coreceptor antagonists. These medications are distributed via hospital pharmacies, online platforms, and retail pharmacies and are utilized by end users such as hospitals, clinics, and specialty treatment centers.

The human immunodeficiency virus therapeutics market research report is one of a series of new reports from The Business Research Company that provides human immunodeficiency virus therapeutics market statistics, including the human immunodeficiency virus therapeutics industry global market size, regional shares, competitors with the human immunodeficiency virus therapeutics market share, detailed human immunodeficiency virus therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the human immunodeficiency virus therapeutics industry. This human immunodeficiency virus therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The human immunodeficiency virus therapeutics market size has grown strongly in recent years. It will grow from$14.11 billion in 2024 to $14.94 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth during the historic period can be attributed to the increasing prevalence of HIV, expansion of awareness initiatives, a rise in diagnostic testing, greater penetration of generic drugs, and the development of healthcare infrastructure.

The human immunodeficiency virus therapeutics market size is expected to see strong growth in the next few years. It will grow to$18.57 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%. The growth during the forecast period can be attributed to an increasing HIV patient population, a rise in HIV screening efforts, growth in voluntary testing rates, a surge in unprotected sexual practices, and the expansion of government-led programs. Major trends in the forecast period include advancements in technology, AI-driven drug development, the emergence of long-acting injectable treatments, the integration of telemedicine, and the exploration of CRISPR-based gene therapies.

The rising incidence of unprotected sexual activity is a key factor propelling the growth of the human immunodeficiency virus (HIV) therapeutics market. Unprotected sex-defined as sexual activity without the use of barrier protection-significantly elevates the risk of sexually transmitted infections (STIs), including HIV. This trend is exacerbated by limited access to contraceptive methods and the absence of comprehensive sex education, particularly among adolescents and young adults. HIV therapeutics play a critical role in suppressing viral load, thereby preventing transmission and improving patient outcomes. For example, according to a November 2024 report from the Centers for Disease Control and Prevention (CDC), 32% of U.S. high school students surveyed in 2023 reported having had sexual intercourse, and 48% did not use a condom during their most recent encounter. These statistics highlight the urgent need for effective HIV interventions and support the growing demand for antiretroviral therapies.

Leading companies in the HIV therapeutics market are advancing combination therapy strategies to improve efficacy, minimize drug resistance, and promote patient adherence. Combination therapy involves using two or more drugs simultaneously to treat HIV, offering several benefits such as improved virologic control, reduced pill burden, and lower risk of resistance development. In December 2022, Gilead Sciences Inc., a U.S.-based biopharmaceutical firm, received FDA approval for Sunlenca (lenacapavir), a novel long-acting capsid inhibitor. Approved for use in combination with other antiretroviral agents, Sunlenca is intended for adults with multidrug-resistant HIV-1. It is the first HIV medication in its class and offers a biannual dosing regimen, which significantly enhances convenience and adherence. The approval was supported by the CAPELLA trial, which demonstrated strong and sustained virologic suppression. Innovations such as Sunlenca are reshaping the treatment landscape, especially for patients with complex therapeutic histories.

In May 2022, F. Hoffmann-La Roche Ltd., a Switzerland-based healthcare and diagnostics leader, entered into a partnership with The Global Fund to strengthen HIV and tuberculosis diagnostics in low- and middle-income countries (LMICs). The initiative aims to scale up access to diagnostic tools, overcome infrastructure barriers, and promote sustainable healthcare waste management practices. The Global Fund, also based in Switzerland, is a global financing mechanism dedicated to supporting healthcare systems in the fight against HIV/AIDS, tuberculosis, and malaria. This collaboration reflects a broader industry trend of public-private partnerships targeting improved disease detection, early treatment, and pandemic preparedness in underserved regions.

Major players in the human immunodeficiency virus therapeutics market are Pfizer Inc., Johnson & Johnson, F Hoffmann La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi SA, Bristol Myers Squibb Company (BMS), Novartis International AG, GlaxoSmithKline plc (GSK), Gilead Sciences Inc., Moderna Inc., BioNTech SE, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Aurobindo Pharma Limited, Cipla Limited, Hetero Labs Limited, Gilead Sciences Inc. / Kite Pharma Inc. (for CAR T HIV cure research), Vir Biotechnology Inc., Theratechnologies Inc., and CytoDyn Inc.

North America was the largest region in the human immunodeficiency virus therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in human immunodeficiency virus therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the human immunodeficiency virus therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The human immunodeficiency virus therapeutics market consists of revenues earned by entities by providing services such as telehealth and remote patient monitoring, patient support and case management services, clinical trials and research services, and HIV testing and diagnosis services. The market value includes the value of related goods sold by the service provider or included within the service offering. The human immunodeficiency virus therapeutics market also includes sales of antiretroviral drugs (ARVs), pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP), and immune system boosters. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Human Immunodeficiency Virus Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on human immunodeficiency virus therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for human immunodeficiency virus therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The human immunodeficiency virus therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Branded Drugs; Generic Drugs
• 2) By Drug Class: Nucleoside-Analog Reverse Transcriptase Inhibitors (Nrtis); Non-Nucleoside Reverse Transcriptase Inhibitors (Nnrtis); Entry And Fusion Inhibitors; Protease Inhibitors (Pis); Integrase Inhibitors; Coreceptor Antagonists
• 3) By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies
• 4) By End-user: Hospitals And Clinics; Specialty Centers
• Subsegments:
• 1) By Branded Drugs: Biktarvy; Triumeq; Genvoya; Juluca; Dovato; Isentress; Prezista
• 2) By Generic Drugs: Tenofovir Disoproxil Fumarate (TDF); Lamivudine; Efavirenz; Zidovudine; Nevirapine; Abacavir; Ritonavir
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F Hoffmann La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Human Immunodeficiency Virus Therapeutics Market Characteristics

3. Human Immunodeficiency Virus Therapeutics Market Trends And Strategies

4. Human Immunodeficiency Virus Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Human Immunodeficiency Virus Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Human Immunodeficiency Virus Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Human Immunodeficiency Virus Therapeutics Market Growth Rate Analysis
• 5.4. Global Human Immunodeficiency Virus Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Human Immunodeficiency Virus Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Human Immunodeficiency Virus Therapeutics Total Addressable Market (TAM)

6. Human Immunodeficiency Virus Therapeutics Market Segmentation

• 6.1. Global Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Branded Drugs
• Generic Drugs
• 6.2. Global Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nucleoside-Analog Reverse Transcriptase Inhibitors (Nrtis)
• Non-Nucleoside Reverse Transcriptase Inhibitors (Nnrtis)
• Entry And Fusion Inhibitors
• Protease Inhibitors (Pis)
• Integrase Inhibitors
• Coreceptor Antagonists
• 6.3. Global Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies
• 6.4. Global Human Immunodeficiency Virus Therapeutics Market, Segmentation By End-user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals And Clinics
• Specialty Centers
• 6.5. Global Human Immunodeficiency Virus Therapeutics Market, Sub-Segmentation Of Branded Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Biktarvy
• Triumeq
• Genvoya
• Juluca
• Dovato
• Isentress
• Prezista
• 6.6. Global Human Immunodeficiency Virus Therapeutics Market, Sub-Segmentation Of Generic Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tenofovir Disoproxil Fumarate (TDF)
• Lamivudine
• Efavirenz
• Zidovudine
• Nevirapine
• Abacavir
• Ritonavir

7. Human Immunodeficiency Virus Therapeutics Market Regional And Country Analysis

• 7.1. Global Human Immunodeficiency Virus Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Human Immunodeficiency Virus Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Human Immunodeficiency Virus Therapeutics Market

• 8.1. Asia-Pacific Human Immunodeficiency Virus Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Human Immunodeficiency Virus Therapeutics Market

• 9.1. China Human Immunodeficiency Virus Therapeutics Market Overview
• 9.2. China Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Human Immunodeficiency Virus Therapeutics Market

• 10.1. India Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Human Immunodeficiency Virus Therapeutics Market

• 11.1. Japan Human Immunodeficiency Virus Therapeutics Market Overview
• 11.2. Japan Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Human Immunodeficiency Virus Therapeutics Market

• 12.1. Australia Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Human Immunodeficiency Virus Therapeutics Market

• 13.1. Indonesia Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Human Immunodeficiency Virus Therapeutics Market

• 14.1. South Korea Human Immunodeficiency Virus Therapeutics Market Overview
• 14.2. South Korea Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Human Immunodeficiency Virus Therapeutics Market

• 15.1. Western Europe Human Immunodeficiency Virus Therapeutics Market Overview
• 15.2. Western Europe Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Human Immunodeficiency Virus Therapeutics Market

• 16.1. UK Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Human Immunodeficiency Virus Therapeutics Market

• 17.1. Germany Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Human Immunodeficiency Virus Therapeutics Market

• 18.1. France Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Human Immunodeficiency Virus Therapeutics Market

• 19.1. Italy Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Human Immunodeficiency Virus Therapeutics Market

• 20.1. Spain Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Human Immunodeficiency Virus Therapeutics Market

• 21.1. Eastern Europe Human Immunodeficiency Virus Therapeutics Market Overview
• 21.2. Eastern Europe Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Human Immunodeficiency Virus Therapeutics Market

• 22.1. Russia Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Human Immunodeficiency Virus Therapeutics Market

• 23.1. North America Human Immunodeficiency Virus Therapeutics Market Overview
• 23.2. North America Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Human Immunodeficiency Virus Therapeutics Market

• 24.1. USA Human Immunodeficiency Virus Therapeutics Market Overview
• 24.2. USA Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Human Immunodeficiency Virus Therapeutics Market

• 25.1. Canada Human Immunodeficiency Virus Therapeutics Market Overview
• 25.2. Canada Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Human Immunodeficiency Virus Therapeutics Market

• 26.1. South America Human Immunodeficiency Virus Therapeutics Market Overview
• 26.2. South America Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Human Immunodeficiency Virus Therapeutics Market

• 27.1. Brazil Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Human Immunodeficiency Virus Therapeutics Market

• 28.1. Middle East Human Immunodeficiency Virus Therapeutics Market Overview
• 28.2. Middle East Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Human Immunodeficiency Virus Therapeutics Market

• 29.1. Africa Human Immunodeficiency Virus Therapeutics Market Overview
• 29.2. Africa Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Human Immunodeficiency Virus Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Human Immunodeficiency Virus Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Human Immunodeficiency Virus Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Human Immunodeficiency Virus Therapeutics Market Competitive Landscape
• 30.2. Human Immunodeficiency Virus Therapeutics Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F Hoffmann La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Human Immunodeficiency Virus Therapeutics Market Other Major And Innovative Companies

• 31.1. Sanofi SA
• 31.2. Bristol Myers Squibb Company (BMS)
• 31.3. Novartis International AG
• 31.4. GlaxoSmithKline plc (GSK)
• 31.5. Gilead Sciences Inc.
• 31.6. Moderna Inc.
• 31.7. BioNTech SE
• 31.8. Teva Pharmaceutical Industries Ltd.
• 31.9. Boehringer Ingelheim International GmbH
• 31.10. Aurobindo Pharma Limited
• 31.11. Cipla Limited
• 31.12. Hetero Labs Limited
• 31.13. Gilead Sciences Inc. / Kite Pharma Inc. (for CAR T HIV cure research)
• 31.14. Vir Biotechnology Inc.
• 31.15. Theratechnologies Inc.

32. Global Human Immunodeficiency Virus Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Human Immunodeficiency Virus Therapeutics Market

34. Recent Developments In The Human Immunodeficiency Virus Therapeutics Market

35. Human Immunodeficiency Virus Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Human Immunodeficiency Virus Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Human Immunodeficiency Virus Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Human Immunodeficiency Virus Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer
• 250617_r34871_Human_Immunodeficiency_Virus_Therapeutics_GMR_2025